38650 Federal Register / Vol. 71, No.
130 / Friday, July 7, 2006 / Notices
Dated: June 28, 2006.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E6–10587 Filed 7–6–06; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Administration for Developmental
Disabilities
Award To: Oregon Health & Science
University, Child Development &
Rehabilitation Center.
Purpose: To supplement a grant
award for support of ‘‘Making It Real:
Participatory Action Research (PAR) for
University Centers for Excellence in
Developmental Disabilities (UCEDDs)’’.
Amount of Award: $65,000 for one
year.
Project Period: 7/1/2006—6/30/2007.
Justification for Exception to
Competition: After consulting with
relevant, informed sources, including
individuals with developmental
disabilities and their families, the
Administration for Developmental
Disabilities (ADD) determined that it
was beneficial to continue funding the
Oregon Health & Science University,
Child Development & Rehabilitation
Center project to strengthen and expand
the inclusion of people with
developmental disabilities and their
family members in participatory action
research projects at University Centers
for Excellence in Developmental
Disabilities (UCEDDs).
The Oregon Institute on Disability &
Development, the Oregon Health and
Science University, Child Development
and Rehabilitation Center will receive a
sole source program expansion
supplemental grant for ‘‘Making It Real:
Participatory Action Research (PAR) for
UCEDDs,’’ a training initiative on the
critical and emerging needs of
individuals with developmental
disabilities and their families. Through
the project, a tool kit is being created
that will include tested educational
modules on participatory action
research. Through the creation of the
toolkit, every UCEDD will be able to
access resources that will enhance and
increase PAR and support initiatives
cprice-sewell on PROD1PC66 with NOTICES
that are most meaningful to people with
developmental disabilities and their
families. It will also be available to
individuals with developmental
disabilities, family members, advocacy
groups, and other interested
VerDate Aug<31>2005 15:46 Jul 06, 2006 Jkt 208001
organizations. By continuing funding of
this project, additional resources will be
developed, including materials in
Spanish. In addition, the expansion
supplement will allow for more time
and resources to enhance training and
dissemination efforts.
The Administration for Children and
Families intends to supplement the
current grant by $65,000. The grantee
will continue to provide a 25 percent
match.
FOR FURTHER INFORMATION CONTACT:
Jennifer G. Johnson, Ed.D., Program
Specialist, Administration on
Developmental Disabilities, 200
Independence Avenue, SW., Room 405–
D, Washington, DC 20201. Telephone:
202/690–5982 (v); 202/205–8037 (f). E-
mail: jennifer.johnson@acf.hhs.gov.
Dated: June 21, 2006.
Patricia A. Morrissey,
Commissioner, Administration for
Developmental Disabilities.
[FR Doc. E6–10578 Filed 7–6–06; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 1990D–0428]
Human-Labeled Drugs Distributed and
Used in Animal Medicine; Withdrawal
of Compliance Policy Guide
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice; withdrawal.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
withdrawal of a compliance policy
guide (CPG) that was issued on March
19, 1991.
DATES: July 7, 2006.
FOR FURTHER INFORMATION CONTACT:
Diane D. Jeang, Division of Compliance
Policy (HFC–230), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 240–632–6833.
SUPPLEMENTARY INFORMATION: In a notice
published in the Federal Register of
July 30, 1992 (57 FR 33729), FDA
announced the availability of a revised
CPG 7125.35 entitled ‘‘Human-Labeled
Drugs Distributed and Used in Animal
Medicine.’’ The CPG is being withdrawn
because it is obsolete. This CPG
explained how FDA would exercise its
enforcement discretion with respect to
the distribution and use of human-
labeled drug products for use in
animals.
The Animal Medicinal Drug Use
Clarification Act of 1994 (AMDUCA)
PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\07JYN1.SGM
was signed into law on October 22,
1994. AMDUCA allows veterinarians to
prescribe extralabel uses of approved
animal drugs and approved human
drugs for animals under certain
conditions. An extralabel use must be
by or on the order of a licensed
veterinarian within the context of a
veterinarian-client-patient relationship
and must be in conformance with the
implementing regulations published in
part 530 (21 CFR part 530). A list of
drugs specifically prohibited from
extralabel use in animals is in § 530.41.
With the enactment of AMDUCA and
the issuance of implementing
regulations, FDA is withdrawing CPG
7125.35 because it is obsolete. On
September 24, 1998, a CPG section
615.100 entitled ‘‘Extralabel Use of New
Animal Drugs in Food-Producing
Animals (CPG 7125.06)’’ was withdrawn
for the same reason (63 FR 51074).
Dated: June 20, 2006.
Margaret O’K. Glavin,
Associate Commissioner for Regulatory
Affairs.
[FR Doc. E6–10672 Filed 7–6–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006D–0214]
Streptomycin Residues in Cattle
Tissues; Withdrawal of Compliance
Policy Guide
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice; withdrawal.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
withdrawal of the compliance policy
guide (CPG) entitled ‘‘Sec. 616.100
Streptomycin Residues in Cattle Tissues
(CPG 7125.22).’’ This CPG is obsolete.
DATES: The withdrawal is effective July
7, 2006.
FOR FURTHER INFORMATION CONTACT:
Diane D. Jeang, Division ofCompliance
Policy (HFC–230), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 240–632–6833.
SUPPLEMENTARY INFORMATION: FDA
issued the CGP entitled ‘‘Sec. 616.100
Streptomycin Residues in Cattle Tissues
(CPG 7125.22)’’ on October 1, 1980. The
CPG was issued because there were no
published tolerances for residues of
streptomycin in cattle tissue and the
available data supported an action level
of 2 part per million (ppm)
streptomycin/dihydrostreptomycin
07JYN1
 Federal Register / Vol. 71, No. 130 / Friday, July 7, 2006 / Notices 38651

residues in cattle kidney tissue. The Dated: June 20, 2006. Proposed Project: The Health Education
U.S. Department of Agriculture, Food Margaret O’K. Glavin, Assistance Loan (HEAL) Program:
Safety Quality Service (now known as Associate Commissioner for Regulatory Forms (OMB No. 0915–0034 Extension)
the Food Safety Inspection Service) Affairs.
agreed to report any detectable residues [FR Doc. E6–10671 Filed 7–6–06; 8:45 am] The HEAL program provides federally
in other edible tissue and to report to BILLING CODE 4160–01–S insured loans to assure the availability
FDA only those cattle kidney tissue of funds for loans to eligible students to
reports where the streptomycin residue pay for their education costs. In order to
was 2 ppm or more. DEPARTMENT OF HEALTH AND administer and monitor the HEAL
HUMAN SERVICES program, the following forms are
Since issuing this CPG, FDA has utilized: The Application for Contract of
established tolerances for Health Resources and Services Federal Loan Insurance form (used by
dihydrostreptomycin (59 FR 41976, Administration lenders to make application to the
August 16, 1994) and streptomycin (58 HEAL insurance program and formerly
FR 47210, September 8, 1993). Agency Information Collection
Activities: Submission for OMB entitled Lenders Application for
Tolerances are established for residues Contract of Federal Loan Insurance
of dihydrostreptomycin in uncooked, Review; Comment Request
form); the Borrower’s Deferment
edible tissues of cattle and swine of 2.0 Request form (used by borrowers to
Periodically, the Health Resources
ppm in kidney and 0.5 ppm in other and Services Administration (HRSA) request deferments on HEAL loans and
tissues, and 0.125 ppm in milk. (See 21 publishes abstracts of information used by lenders to determine borrower’s
CFR 556.200.) Tolerances are collection requests under review by the eligibility for deferment); the Borrower
established for residues of streptomycin Office of Management and Budget Loan Status update electronic
in uncooked, edible tissues of chickens, (OMB), in compliance with the submission (submitted monthly by
swine, and calves of 2.0 ppm in kidney, Paperwork Reduction Act of 1995 (44 lenders to the Secretary on the status of
and 0.5 ppm in other tissues. (See 21 U.S.C. chapter 35). To request a copy of each loan); and the Loan Purchase/
CFR 556.610.) the clearance requests submitted to Consolidation electronic submission
FDA is withdrawing CPG 7125.22, in OMB for review, call the HRSA Reports (submitted by lenders to the Secretary to
its entirety, to eliminate obsolete Clearance Office on (301) 443–1129. report sales, and purchases of HEAL
compliance policy. The following request has been
submitted to the Office of Management loans).
and Budget for review under the The estimates of burden for the forms
Paperwork Reduction Act of 1995: are as follows:

Responses
Number of Total Hours per Total burden
Collection activity per
respondents responses response hours
respondent

Application for Contract of Federal Loan Insurance .............. 17 1 17 8 min ........... 3

Borrower’s Deferment Request:
Borrowers ........................................................................ 436 1 436 10 min ......... 73
Employers ....................................................................... 261 1.669 436 5 min ........... 36
Borrower Loan Status Update ................................................ 8 18 144 10 min ......... 24
Loan Purchase/Consolidation ................................................ 17 248 4,216 4 min ........... 281

Total ................................................................................ 739 ........................ 5,249 ..................... 417

Written comments and DEPARTMENT OF HEALTH AND and personal information concerning
recommendations concerning the HUMAN SERVICES individuals associated witht he grant
proposed information collection should applications, the disclosure of which
be sent within 30 days of this notice to: National Institutes of Health would constitute a clearly unwarranted
John Kraemer, Human Resources and invasion of personal property.
Office of the Director, National
Housing Branch, Office of Management Name of Committee: Advisory Committee
Institutes of Health; Notice of Closed
and Budget, New Executive Office to the Director, NIH.
Meeting
Building, Room 10235, Washington, DC Date: August 17, 2006.
20503. Pursuant to section 10(d) of the Time: 2 p.m. to 3 p.m.
Dated: June 29, 2006.
Federal Advisory Committee Act, as Place: National Institutes of Health,
amended (5 U.S.C. Appendix 2), notice Building 31, 31 Center Drive, Room 5B64,
Cheryl R. Dammons, is hereby given of a meeting of the Bethesda, MD 20892.
Director, Division of Policy Review and Advisory Committee to the Director, Agenda: To review and evaluate grant
Coordination. National Institutes of Health (NIH). applications (Telephone Conference Call).
[FR Doc. E6–10591 Filed 7–6–06; 8:45 am] The meeting will be closed to the Contact Person: Shelly Pollard, ACD
public in accordance with the
cprice-sewell on PROD1PC66 with NOTICES

BILLING CODE 4165–15–P Coordinator, National Institutes of Health,

provisions set forth in sections 9000 Rockville Pike, Building 31, Room
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 5B64, Bethesda, MD 20892, (301) 496–0959,
as amended. The grant applications and pollards@mail.nih.gov.
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,

VerDate Aug<31>2005 17:24 Jul 06, 2006 Jkt 208001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\07JYN1.SGM 07JYN1